Physician profile
Gary E Oppenheim
NPI 1083639249
$152,860.29
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79K · 2020: $21K · 2021: $41K · 2022: $8,715 · 2023: $3,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,501 · Food and Beverage: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,500.50 |
| Food and Beverage | $131.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $57,553.38 | 2019-2022 | |
| Amgen INC. | $31,219.39 | 2019-2023 | Repatha |
| Novo Nordisk INC | $18,553.56 | 2019-2021 | |
| Lilly USA, LLC | $16,631.87 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $8,100.74 | 2019 | |
| Amarin Pharma, INC. | $7,917.76 | 2020 | |
| Sanofi-Aventis U.S. LLC | $5,425.64 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $4,110.10 | 2019 | |
| Boston Scientific Corporation | $3,143.32 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $112.28 | 2021 | |
| Impulse Dynamics (USA) INC. | $62.30 | 2022 | |
| Esperion Therapeutics, INC. | $29.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Oppenheim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.